Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform. This… Read More
DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access. DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as… Read More
The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T… Read More
Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More
New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment… Read More
The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with… Read More
Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)… Read More
